Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
J Hepatol
    September 2025
  1. DALEKOS GN, Gatselis N, Tiniakos D
    EASL CPG: Liver biopsy cannot be skipped for the diagnosis of autoimmune hepatitis.
    J Hepatol. 2025 Sep 3:S0168-8278(25)02468-7. doi: 10.1016/j.jhep.2025.
    >> Share

    August 2025
  2. HOFMANN M, Rehermann B
    T Cells in a Drop: Rapid T Cell Monitoring in Chronic Hepatitis B.
    J Hepatol. 2025 Aug 22:S0168-8278(25)02443-2. doi: 10.1016/j.jhep.2025.
    >> Share

    July 2025
  3. SANDMANN L
    From HCV to HEV: Repurposing a nucleoside analogue for hepatitis E therapy.
    J Hepatol. 2025 Jul 31:S0168-8278(25)02322-0. doi: 10.1016/j.jhep.2025.
    >> Share

  4. HON-YIN LO K, Stanley Ho SF, Hon-Kiu Shun E, Wu S, et al
    Enhanced surveillance, subtyping, and host adaptation analysis reveal genotype-wide zoonotic potential of rat hepatitis E virus.
    J Hepatol. 2025 Jul 14:S0168-8278(25)02339-6. doi: 10.1016/j.jhep.2025.
    >> Share

  5. BJORNSSON ES, Hirschfield GM
    The role of liver biopsy in diagnosing patients with autoimmune hepatitis- it can be acceptable to skip!
    J Hepatol. 2025 Jul 1:S0168-8278(25)02315-3. doi: 10.1016/j.jhep.2025.
    >> Share

    June 2025
  6. CHEN Z, Liu L, Situ J, Li G, et al
    Antibodies elicited by hepatitis E vaccination in humans confer cross-genus protection against rat hepatitis E virus.
    J Hepatol. 2025 Jun 24:S0168-8278(25)02283-4. doi: 10.1016/j.jhep.2025.
    >> Share

  7. MUELLER LJ, Schmidt ML, Ciesek S, Corman VM, et al
    Presence but low detection rate of rat Hepatitis E Virus in patients in Germany 2022-2024.
    J Hepatol. 2025 Jun 5:S0168-8278(25)02256-1. doi: 10.1016/j.jhep.2025.
    >> Share

  8. LIU T, Yang X, Zhang H, Yin X, et al
    Prior Hepatitis E virus (HEV) genotype 1 infection is not protective against rat HEV infection in Mongolian gerbils.
    J Hepatol. 2025 Jun 4:S0168-8278(25)02254-8. doi: 10.1016/j.jhep.2025.
    >> Share

  9. BOZWARD AG, Davies SP, Morris SM, Kayani K, et al
    Cellular interactions in self-directed immune-mediated liver diseases.
    J Hepatol. 2025;82:1110-1124.
    >> Share

    May 2025
  10. LOK J, Cargill Z, Anderson M, Cloherty G, et al
    Re: Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta.
    J Hepatol. 2025 May 28:S0168-8278(25)02257-3. doi: 10.1016/j.jhep.2025.
    >> Share


  11. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
    J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.
    >> Share


  12. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2025 May 8:S0168-8278(25)00174-6. doi: 10.1016/j.jhep.2025.
    >> Share

  13. SCHWARZ T, Ptok J, Damagnez M, Menne C, et al
    HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replication.
    J Hepatol. 2025;82:805-815.
    >> Share

    April 2025
  14. HOUGHTON M
    A rat hepacivirus model to aid hepatitis C viral vaccine development ?
    J Hepatol. 2025 Apr 16:S0168-8278(25)00243-0. doi: 10.1016/j.jhep.2025.
    >> Share

  15. SANDMANN L
    Toward functional cure of hepatitis B: Is combination therapy the key?
    J Hepatol. 2025 Apr 15:S0168-8278(25)00212-0. doi: 10.1016/j.jhep.2025.
    >> Share

  16. FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
    Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
    >> Share

  17. MONTES MG, Caraballo LL, Sousa Martin JM
    REPLY TO "UPDATE IN CLINICAL SCIENCE: AUTOIMMUNE HEPATITIS": USE OF ENTERIC-COATED MYCOPHENOLATE SODIUM AS A THERAPEUTIC OPTION FOR AUTOIMMUNE HEPATITIS.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00228-4. doi: 10.1016/j.jhep.2025.
    >> Share

  18. CORMAN VM, Schwarz T, Steinmann E
    Rat hepatitis E virus: the new kid on the block?
    J Hepatol. 2025 Apr 9:S0168-8278(25)00218-1. doi: 10.1016/j.jhep.2025.
    >> Share

  19. LUHMANN N, Wedemeyer H
    More than 10 years of IFN-free HCV treatment and viral hepatitis elimination: Mission not completed!
    J Hepatol. 2025 Apr 8:S0168-8278(25)00220-X. doi: 10.1016/j.jhep.2025.
    >> Share

  20. BUTI M, Riveiro-Barciela M, Forns X
    Rat Hepatitis E: A Silent Threat or Overestimated Risk?
    J Hepatol. 2025 Apr 2:S0168-8278(25)00217-X. doi: 10.1016/j.jhep.2025.
    >> Share

  21. JIN F, Gridley J, Kumari A, Saeidi A, et al
    Hyperfunctional T cell responses unchecked by regulatory T cells are unable to resolve hepaciviral infection without humoral contribution.
    J Hepatol. 2025;82:604-614.
    >> Share

    March 2025
  22. THORSELIUS CE, Wolfisberg R, Fahnoe U, Scheel TKH, et al
    Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host evolution and escape from neutralizing antibodies.
    J Hepatol. 2025 Mar 15:S0168-8278(25)00163-1. doi: 10.1016/j.jhep.2025.
    >> Share

  23. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
    Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
    >> Share

    February 2025
  24. HUANG SC, Su TH
    Divergent Roles of MASLD Components in Chronic Hepatitis B: A Double-Edged Sword.
    J Hepatol. 2025 Feb 28:S0168-8278(25)00144-8. doi: 10.1016/j.jhep.2025.
    >> Share

  25. CABALLERO-GOMEZ J, Casares-Jimenez M, Gallo-Marin M, Pereira-Pardo S, et al
    Rat hepatitis E virus as an aetiological agent of acute hepatitis of unknown origin.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00136-9. doi: 10.1016/j.jhep.2025.
    >> Share

  26. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
    Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
    >> Share

  27. WANG J, Zhang S, Zhu C, Wu C, et al
    Treatment coverage of the 2024 updated WHO guidelines for patients with chronic hepatitis B.
    J Hepatol. 2025 Feb 8:S0168-8278(25)00077-7. doi: 10.1016/j.jhep.2025.
    >> Share

  28. LAI JC, Cai J, Yip TC
    Reply to: "Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective".
    J Hepatol. 2025 Feb 8:S0168-8278(25)00076-5. doi: 10.1016/j.jhep.2025.
    >> Share

  29. RAZAVI HA, Waked I, Qureshi H, Kondili LA, et al
    Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00020-0. doi: 10.1016/j.jhep.2025.
    >> Share

  30. LI F, Qu L, Liu Y, Wu X, et al
    PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial.
    J Hepatol. 2025;82:211-221.
    >> Share

  31. HAN Y, Tang J, Hu P, Ren H, et al
    Metabolic dysfunction-associated steatotic liver disease may increase intrahepatic interferon gene signatures in patients with chronic hepatitis B.
    J Hepatol. 2025 Feb 1:S0168-8278(25)00073-X. doi: 10.1016/j.jhep.2025.
    >> Share

    January 2025
  32. WANG J, Zhang S, Zhu C, Wu C, et al
    Increased HBsAg loss in HBeAg-negative patients with chronic hepatitis B and concurrent MASLD.
    J Hepatol. 2025 Jan 29:S0168-8278(25)00059-5. doi: 10.1016/j.jhep.2025.
    >> Share

  33. HENEGHAN MA, Lohse AW
    Update in Clinical Science: Autoimmune Hepatitis.
    J Hepatol. 2025 Jan 24:S0168-8278(24)02832-0. doi: 10.1016/j.jhep.2024.
    >> Share

  34. SANDMANN L
    Antiviral treatment of chronic hepatitis D virus infection: To combine or not to combine?
    J Hepatol. 2025 Jan 20:S0168-8278(24)02820-4. doi: 10.1016/j.jhep.2024.
    >> Share

  35. DEGASPERI E, Anolli MP, Jachs M, Reiberger T, et al
    Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
    J Hepatol. 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
    >> Share

    December 2024
  36. WAN-HIN HUI R, Mak LY, Yuen MF
    Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNalpha based therapy".
    J Hepatol. 2024 Dec 24:S0168-8278(24)02821-6. doi: 10.1016/j.jhep.2024.
    >> Share

  37. SHIN H, Hur MH, Song BG, Park SY, et al
    AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B.
    J Hepatol. 2024 Dec 20:S0168-8278(24)02784-3. doi: 10.1016/j.jhep.2024.
    >> Share

  38. GAO G, Guo J, Yu G, Li GF, et al
    Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: A Sensitivity Analysis Quantifying Effect of Unmeasured Confounding factors on Observational Associations.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02777-6. doi: 10.1016/j.jhep.2024.
    >> Share

  39. WANG C, Tian H, Shang J
    Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine research.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02778-8. doi: 10.1016/j.jhep.2024.
    >> Share

  40. HUANG SC, Su TH, Tseng TC, Hsu SJ, et al
    All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease.
    J Hepatol. 2024 Dec 13:S0168-8278(24)02763-6. doi: 10.1016/j.jhep.2024.
    >> Share

  41. DEGASPERI E, Scholtes C, Testoni B, Renteria SU, et al
    Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta.
    J Hepatol. 2024 Dec 9:S0168-8278(24)02759-4. doi: 10.1016/j.jhep.2024.
    >> Share

  42. LAI-HUNG WONG G, Lemoine M
    The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines.
    J Hepatol. 2024 Dec 6:S0168-8278(24)02755-7. doi: 10.1016/j.jhep.2024.
    >> Share

    November 2024
  43. DONGELMANS EJ, Janssen HLA
    Reply to "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.".
    J Hepatol. 2024 Nov 29:S0168-8278(24)02746-6. doi: 10.1016/j.jhep.2024.
    >> Share

  44. OKAMOTO T, Hatano E
    Reply to: "Could the paediatric acute hepatitis of unknown origin be related to a new autoimmune disease?".
    J Hepatol. 2024 Nov 29:S0168-8278(24)02747-8. doi: 10.1016/j.jhep.2024.
    >> Share

  45. SHIN YE, Kim JY, Yoo JJ, Kim SG, et al
    Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02722-3. doi: 10.1016/j.jhep.2024.
    >> Share

  46. SHEN M, He S, Yao N, Li R, et al
    Real-world clinical data-driven modelling on the initiation time of antiviral prophylaxis among pregnant women with chronic hepatitis B infection.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02717-X. doi: 10.1016/j.jhep.2024.
    >> Share

  47. CHE-TO LAI J, Wong GL, Tse YK, Hui VW, et al
    Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02718-1. doi: 10.1016/j.jhep.2024.
    >> Share

  48. LIU Y, Wei Y, Chen X, Huang S, et al
    Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils East Asian etiology linked to historic HBV epidemic.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024.
    >> Share

  49. HUR MH, Lee JH
    Reply to "A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024.
    >> Share

  50. MON HC, Huang YH
    Reply to "Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?" and "Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02701-6. doi: 10.1016/j.jhep.2024.
    >> Share

  51. HUI RW, Mak LY, Yuen MF
    Reply to: "Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio".
    J Hepatol. 2024 Nov 6:S0168-8278(24)02657-6. doi: 10.1016/j.jhep.2024.
    >> Share

  52. BAHCECI D, Hameed B, Gill RM
    Granulomatous hepatitis, a mystery solved.
    J Hepatol. 2024;81:e215-e217.
    >> Share

  53. TONIUTTO P, Falleti E, Cmet S, Cussigh A, et al
    Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
    J Hepatol. 2024;81:819-826.
    >> Share

    October 2024
  54. OSMANI Z, Brouwer WP, Grashof DGB, Lim Y, et al
    Metabolic dysfunction-associated steatohepatitis reduces interferon and macrophage liver gene signatures in patients with chronic hepatitis B.
    J Hepatol. 2024 Oct 26:S0168-8278(24)02653-9. doi: 10.1016/j.jhep.2024.
    >> Share

  55. LIU YC, Liaw YF
    The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.
    J Hepatol. 2024 Oct 18:S0168-8278(24)02638-2. doi: 10.1016/j.jhep.2024.
    >> Share

  56. CHEUK-FUNG YIP T, Peng N, Che-To Lai J
    Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B - Reply to Di et al. and Huang et al.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02633-3. doi: 10.1016/j.jhep.2024.
    >> Share

  57. WANG J, Zhang Q, Zhang S, Wu C, et al
    ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFN-alpha-based therapy.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02628-X. doi: 10.1016/j.jhep.2024.
    >> Share

  58. XIAO G, Ren H
    Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B.
    J Hepatol. 2024 Oct 16:S0168-8278(24)02630-8. doi: 10.1016/j.jhep.2024.
    >> Share

  59. MARTINEZ-LASO J, Cervera I, Munoz M, Casas I, et al
    Could the paediatric acute hepatitis of unknown origin be related to a new autoimmune disease?
    J Hepatol. 2024 Oct 15:S0168-8278(24)02626-6. doi: 10.1016/j.jhep.2024.
    >> Share

  60. SLOOTER CD, Stoelinga AEC, Snijders RJALM
    Reply to: Obtaining first-line induction in autoimmune hepatitis: aren't we underestimating prednisolone?
    J Hepatol. 2024 Oct 4:S0168-8278(24)02580-7. doi: 10.1016/j.jhep.2024.
    >> Share

  61. LIU CH, Cheng PN, Fang YJ, Chen CY, et al
    Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection.
    J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.
    >> Share

  62. PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al
    Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    J Hepatol. 2024;81:590-599.
    >> Share

  63. WEDEMEYER H, Aleman S, Brunetto M, Blank A, et al
    Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
    J Hepatol. 2024;81:621-629.
    >> Share

    September 2024
  64. CUI Y
    Community Health Strategies for Chronic Hepatitis B: Advancing Care with the ALT/qHBsAg Ratio.
    J Hepatol. 2024 Sep 30:S0168-8278(24)02575-3. doi: 10.1016/j.jhep.2024.
    >> Share

  65. LUO J, Gao B, Li B
    Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?
    J Hepatol. 2024 Sep 27:S0168-8278(24)02571-6. doi: 10.1016/j.jhep.2024.
    >> Share

  66. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
    AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
    J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
    >> Share

  67. XIAO G, Ren H
    A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
    J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024.
    >> Share

  68. CHUNG CY, Wang SH, Yeh SH, Chen PJ, et al
    Reply to: Hepatitis B Virus spliced 1 RNA, a key factor for viral expression.
    J Hepatol. 2024 Sep 10:S0168-8278(24)02545-5. doi: 10.1016/j.jhep.2024.
    >> Share

  69. WU JL, Luo JY, Jiang ZB
    Association between antiviral treatments and fracture in elderly patients with HBV needs further evaluation.
    J Hepatol. 2024;81:e108-e109.
    >> Share

    August 2024
  70. DONGELMANS EJ, Hirode G, Hansen BE, Chen CH, et al
    Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study).
    J Hepatol. 2024 Aug 31:S0168-8278(24)02493-0. doi: 10.1016/j.jhep.2024.
    >> Share

  71. KUDARAVALLI S, Henry L, Nguyen MH
    Integrating Strategic, Equity, and Socioeconomic Perspectives: A Holistic Approach to Advancing Hepatitis B Management and Outcomes.
    J Hepatol. 2024 Aug 30:S0168-8278(24)02491-7. doi: 10.1016/j.jhep.2024.
    >> Share

  72. HUR MH, Yip TC, Kim SU, Lee HW, et al
    A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B.
    J Hepatol. 2024 Aug 30:S0168-8278(24)02494-2. doi: 10.1016/j.jhep.2024.
    >> Share

  73. BUTI M, Heo J, Tanaka Y, Andreone P, et al
    Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.
    J Hepatol. 2024 Aug 28:S0168-8278(24)02488-7. doi: 10.1016/j.jhep.2024.
    >> Share

  74. KIM SY, Shin EC
    Reply to: "Regulatory T cells dynamics during and after chronic hepatitis C treatment".
    J Hepatol. 2024 Aug 19:S0168-8278(24)02476-0. doi: 10.1016/j.jhep.2024.
    >> Share

  75. CUI A, Chung RT, Alatrakchi N
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance - Reply.
    J Hepatol. 2024 Aug 19:S0168-8278(24)02474-7. doi: 10.1016/j.jhep.2024.
    >> Share

    July 2024
  76. LOEFFEN EAH, Verkade HJ, van Rheenen PF
    Obtaining first-line induction in autoimmune hepatitis: aren't we underestimating prednisolone?
    J Hepatol. 2024 Jul 30:S0168-8278(24)02427-9. doi: 10.1016/j.jhep.2024.
    >> Share

  77. WANG Y, Guo X, Yuan Y
    Addressing Bias and Improving Research on Gender and Racial Disparities in Hepatitis B Assessment and Treatment.
    J Hepatol. 2024 Jul 30:S0168-8278(24)02428-0. doi: 10.1016/j.jhep.2024.
    >> Share

  78. VENZIN V, Beccaria CG, Andreata F, Fumagalli V, et al
    Intrahepatic immunity to hepatitis B virus.
    J Hepatol. 2024 Jul 30:S0168-8278(24)00364-7. doi: 10.1016/j.jhep.2024.
    >> Share

  79. MON HC, Lee PC, Hung YP, Hung YW, et al
    Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.
    J Hepatol. 2024 Jul 29:S0168-8278(24)02425-5. doi: 10.1016/j.jhep.2024.
    >> Share

  80. DI J, Song L, Xiang C
    Synergy between public health policy and clinicians plays a key role in reducing fracture risk in patients with viral hepatitis.
    J Hepatol. 2024 Jul 27:S0168-8278(24)02431-0. doi: 10.1016/j.jhep.2024.
    >> Share

  81. SOLIMAN R, Hassan A, Shiha G
    Regulatory T Cells dynamics during and after Chronic Hepatitis C treatment.
    J Hepatol. 2024 Jul 20:S0168-8278(24)02417-6. doi: 10.1016/j.jhep.2024.
    >> Share

  82. RUI F, Ni W, Shi J, Xie Q, et al
    Superior Diagnostic Efficacy of AGILE 3+ Score for Diagnosing Advanced Fibrosis in Chronic Hepatitis B patients with Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Hepatol. 2024 Jul 20:S0168-8278(24)02416-4. doi: 10.1016/j.jhep.2024.
    >> Share

  83. BUTI M, Wedemeyer H, Aleman S, Chulanov V, et al
    Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the Phase III MYR301 trial of bulevirtide.
    J Hepatol. 2024 Jul 13:S0168-8278(24)02337-7. doi: 10.1016/j.jhep.2024.
    >> Share

  84. MINAMI T, Fujishiro M, Tateishi R
    Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score".
    J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024.
    >> Share

  85. ZHANG JW, Lai RM, Wang LF, Wang SL, et al
    Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.
    J Hepatol. 2024 Jul 9:S0168-8278(24)02338-9. doi: 10.1016/j.jhep.2024.
    >> Share

  86. KUNDU J, Le HT, Logan M, Hockman D, et al
    Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
    J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024.
    >> Share

  87. TAK WY, Chuang WL, Chen CY, Tseng KC, et al
    Phase 1b/2a randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with chronic hepatitis B.
    J Hepatol. 2024 Jul 5:S0168-8278(24)02333-X. doi: 10.1016/j.jhep.2024.
    >> Share

  88. ZOULIM F, Chen PJ, Dandri M, Kennedy P, et al
    Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome.
    J Hepatol. 2024 Jul 4:S0168-8278(24)02343-2. doi: 10.1016/j.jhep.2024.
    >> Share

  89. KUDARAVALLI S, Huang DQ, Yeh ML, Trinh L, et al
    Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.
    J Hepatol. 2024;81:33-41.
    >> Share

  90. RICCO G, Brunetto MR
    Reply to: "Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies".
    J Hepatol. 2024;81:e51-e53.
    >> Share

  91. GHANY MG, Buti M, Lampertico P, Lee HM, et al
    Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies".
    J Hepatol. 2024;81:e26-e27.
    >> Share

  92. ANDERSON M, Holzmayer V, Stec M, Cloherty G, et al
    Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies.
    J Hepatol. 2024;81:e24-e25.
    >> Share

  93. PATMORE LA, van der Eijk AA, Janssen HLA, de Man RA, et al
    Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies.
    J Hepatol. 2024;81:e49-e50.
    >> Share

  94. YU H, Ren J, Deng H, Li L, et al
    Neuropilin-1 is a novel host factor modulating the entry of hepatitis B virus.
    J Hepatol. 2024 Jul 1:S0168-8278(24)02339-0. doi: 10.1016/j.jhep.2024.
    >> Share

    June 2024
  95. SLOOTER CD, Stoelinga AEC, Snijders RJALM
    Reply: Mycophenolate Mofetil in Autoimmune Hepatitis: Are We Ready for Primetime?
    J Hepatol. 2024 Jun 15:S0168-8278(24)02318-3. doi: 10.1016/j.jhep.2024.
    >> Share

  96. ZHANG H, Huang J, Zhu W, Feng W, et al
    Does long-term use of tenofovir disoproxil fumarate affect fracture risk in patients with chronic hepatitis B?
    J Hepatol. 2024 Jun 13:S0168-8278(24)02308-0. doi: 10.1016/j.jhep.2024.
    >> Share

  97. KIM SY, Koh JY, Lee DH, Kim HD, et al
    Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02317-1. doi: 10.1016/j.jhep.2024.
    >> Share

  98. PATMORE LA, Sonneveld MJ
    Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
    J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024.
    >> Share

  99. CHUNG CY, Sun CP, Tao MH, Wu HL, et al
    Major HBV splice variant encoding a novel protein important for infection.
    J Hepatol. 2024;80:858-867.
    >> Share

  100. XU M, Warner C, Duan X, Cheng Z, et al
    HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1alpha- and TGF-beta1-dependent pathway.
    J Hepatol. 2024;80:868-881.
    >> Share

    May 2024
  101. REIBERGER T, Lens S, Cabibbo G, Nahon P, et al
    EASL position paper on clinical follow-up after HCV cure.
    J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024.
    >> Share

  102. MCCOULLOUGH LC, Fareh M, Hu W, Sozzi V, et al
    CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein expression.
    J Hepatol. 2024 May 28:S0168-8278(24)00360-X. doi: 10.1016/j.jhep.2024.
    >> Share

  103. ZHANG Y, Zhou Y
    Enhancing Hepatitis B Management: The Role of Political, Economic, and Educational Considerations in Addressing Global Disparities.
    J Hepatol. 2024 May 24:S0168-8278(24)00357-X. doi: 10.1016/j.jhep.2024.
    >> Share

  104. LI H, Guo Q, Guo C
    A Strategic Approach: Three-Tiered Management for Enhancing Global Hepatitis B Outcomes.
    J Hepatol. 2024 May 22:S0168-8278(24)00358-1. doi: 10.1016/j.jhep.2024.
    >> Share

  105. GOMEZ-MORENO A, Guo J, Temple HM, Ploss A, et al
    Formation and transcriptional regulation of hepatitis B virus covalently closed circular DNA.
    J Hepatol. 2024 May 22:S0168-8278(24)00159-4. doi: 10.1016/j.jhep.2024.
    >> Share

  106. CHAPUS F, Giraud G, Huchon P, Roda M, et al
    Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes.
    J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024.
    >> Share

  107. COLAPIETRO F, Lleo A
    Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With Autoimmune Hepatitis?
    J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024.
    >> Share

  108. LAI JC, Yip TC, Wong GL
    Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B - Reply to Wu et al.
    J Hepatol. 2024 May 17:S0168-8278(24)00344-1. doi: 10.1016/j.jhep.2024.
    >> Share

  109. WEN Z
    Enhancing the understanding of the risk of incident fracture in entecavir- and TDF-treated elderly patients with chronic hepatitis B (CHB).
    J Hepatol. 2024 May 16:S0168-8278(24)00347-7. doi: 10.1016/j.jhep.2024.
    >> Share

  110. SHIHA G, Mikhail N, Soliman R
    Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score.
    J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024.
    >> Share

  111. BABLON P, Goy C, Dang HN, Sotty J, et al
    Hepatitis B Virus spliced 1 RNA, a key factor for viral expression.
    J Hepatol. 2024 May 9:S0168-8278(24)00331-3. doi: 10.1016/j.jhep.2024.
    >> Share

  112. YANG F, Fan X, Zhou L, Yang L, et al
    Need for risk stratification in treatment of patients with autoimmune hepatitis.
    J Hepatol. 2024 May 9:S0168-8278(24)00338-6. doi: 10.1016/j.jhep.2024.
    >> Share

  113. VAN OORSCHOT E, Koc OM, Koek GH
    Osteoporosis in hepatitis B patients receiving tenofovir disoproxil fumarate: does fibroblast growth factor 23 play a role?
    J Hepatol. 2024 May 2:S0168-8278(24)00323-4. doi: 10.1016/j.jhep.2024.
    >> Share

  114. QI R, Fu R, Lei X, He J, et al
    Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.
    J Hepatol. 2024;80:714-729.
    >> Share

    April 2024
  115. HEGARTY R, Hadzic N
    GENOMIC TESTING FOR INBORN ERRORS OF IMMUNITY IN SERONEGATIVE AUTOIMMUNE HEPATITIS OF CHILDHOOD.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00289-7. doi: 10.1016/j.jhep.2024.
    >> Share

  116. TAN MY, Su JH
    Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
    >> Share

  117. KENNEDY MJ, Fernbach S, Scheel TKH
    Animal hepacivirus models for hepatitis C virus immune responses and pathology.
    J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023.
    >> Share

  118. UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al
    B cell characteristics define HCV reinfection outcome.
    J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.
    >> Share

  119. AGARWAL K, Buti M, van Bommel F, Lampertico P, et al
    JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
    J Hepatol. 2024 Apr 5:S0168-8278(24)00231-9. doi: 10.1016/j.jhep.2024.
    >> Share

  120. KONDILI LA, Lazarus JV, Jepsen P, Murray F, et al
    Inequities in primary liver cancer in Europe: The state of play.
    J Hepatol. 2024;80:645-660.
    >> Share

    March 2024
  121. BJORNSSON ES, Lucena MI, Andrade RJ
    Reply to the Letter to the Editor: Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface.
    J Hepatol. 2024 Mar 28:S0168-8278(24)00221-6. doi: 10.1016/j.jhep.2024.
    >> Share

  122. SNIJDERS RJALM, Stoelinga AEC, van Hoek B, Drenth JPH, et al
    Prednisolone with azathioprine or mycophenolate mofetil as first-line therapy in autoimmune hepatitis: insights from a randomized controlled trial.
    J Hepatol. 2024 Mar 28:S0168-8278(24)00222-8. doi: 10.1016/j.jhep.2024.
    >> Share

  123. HIN-MAN LEUNG R, Wan-Hin Hui R, Mak LY, Mao X, et al
    ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00204-6. doi: 10.1016/j.jhep.2024.
    >> Share

  124. PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al
    Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024.
    >> Share

  125. PLAGIANNAKOS CG, Hirschfield GM, Lytvyak E, Roberts SB, et al
    Treatment response and clinical event-free survival in autoimmune hepatitis: a Canadian multicentre cohort study.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00205-8. doi: 10.1016/j.jhep.2024.
    >> Share

  126. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
    >> Share

  127. BISWAS S, Shalimar
    Mycophenolate Mofetil in Autoimmune Hepatitis: Are We Ready for Primetime?
    J Hepatol. 2024 Mar 20:S0168-8278(24)00201-0. doi: 10.1016/j.jhep.2024.
    >> Share

  128. TONNERRE P, Baumert TF
    Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B using scRNASeq.
    J Hepatol. 2024 Mar 19:S0168-8278(24)00200-9. doi: 10.1016/j.jhep.2024.
    >> Share

  129. THURSZ M, Mathurin P
    Targeting IL-1 in severe alcohol-related hepatitis; how many frogs will we need to kiss to find an effective therapy?
    J Hepatol. 2024 Mar 16:S0168-8278(24)00163-6. doi: 10.1016/j.jhep.2024.
    >> Share

  130. JACHS M, Sandmann L, Hartl L, Tergast T, et al
    Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
    >> Share

  131. SEITZ S, Bartenschlager R
    Cutting edges in the hepatitis B virus genome: How RNA splicing is involved in modulating virus ultrastructure to promote infection.
    J Hepatol. 2024 Mar 7:S0168-8278(24)00148-X. doi: 10.1016/j.jhep.2024.
    >> Share

  132. SIMSEK C, Wahlin S, Efe C
    Autoimmune Hepatitis: Mycophenolate mofetil versus azathioprine as first line therapy.
    J Hepatol. 2024 Mar 6:S0168-8278(24)00142-9. doi: 10.1016/j.jhep.2024.
    >> Share

  133. SHEEHAN Y, Grebely J, Lloyd AR
    Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
    J Hepatol. 2024;80:e107-e108.
    >> Share

    February 2024
  134. NARMADA BC, Khakpoor A, Shirgaonkar N, Narayanan S, et al
    Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity.
    J Hepatol. 2024 Feb 27:S0168-8278(24)00137-5. doi: 10.1016/j.jhep.2024.
    >> Share

  135. ALRIC L
    Should MMF treatment be the first-line therapy in autoimmune hepatitis?
    J Hepatol. 2024 Feb 23:S0168-8278(24)00134-X. doi: 10.1016/j.jhep.2024.
    >> Share

  136. TIWARI A, Khanikar D, Rathod SG
    "Autoimmune Hepatitis: Azathioprine or Mycophenolate Mofetil for inducing remission?".
    J Hepatol. 2024 Feb 23:S0168-8278(24)00132-6. doi: 10.1016/j.jhep.2024.
    >> Share

  137. BIALLAS R, Zimmermann R, Dudareva S
    Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
    J Hepatol. 2024 Feb 23:S0168-8278(24)00133-8. doi: 10.1016/j.jhep.2024.
    >> Share

  138. YANG H, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!'.
    J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024.
    >> Share

  139. GAWRIEH S, Dasarathy S, Tu W, Kamath PS, et al
    Randomized-controlled trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis.
    J Hepatol. 2024 Feb 9:S0168-8278(24)00109-0. doi: 10.1016/j.jhep.2024.
    >> Share

  140. ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al
    Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024.
    >> Share

  141. LIU C, Guo C, Liu K
    Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and their clinical significance.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024.
    >> Share

  142. HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al
    JAK1 promotes HDV replication and is a potential target for antiviral therapy.
    J Hepatol. 2024;80:220-231.
    >> Share

  143. HIRSCHFIELD GM, Lohse AW
    Editorial: Treating Autoimmune Hepatitis - more science, more progress, better therapy.
    J Hepatol. 2024 Feb 1:S0168-8278(24)00098-9. doi: 10.1016/j.jhep.2024.
    >> Share

  144. ALKASHASH A, Zhang X, Vuppalanchi R, Lammert C, et al
    Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface.
    J Hepatol. 2024 Feb 1:S0168-8278(24)00100-4. doi: 10.1016/j.jhep.2024.
    >> Share

    January 2024
  145. FAN X, Yang F, Zhou L, Yang L, et al
    Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
    >> Share

  146. HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al
    Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study.
    J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.
    >> Share

  147. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
    Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
    >> Share

  148. THOMPSON LA, Charlton CL
    Evaluation and comparison of risk-based and universal HCV screening programs.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023.
    >> Share

  149. ZHANG Y, Bourgine M, Wan Y, Song J, et al
    Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
    J Hepatol. 2024;80:31-40.
    >> Share

  150. TROVATO FM, McPhail M
    Reply to: "Dysregulation of the LPC-ATX-LPA axis in autoimmune hepatitis is associated with monocyte activation": Autotaxin upregulation in liver failure and the effect on monocyte phenotype and function is a pan-aetiology phenomenon.
    J Hepatol. 2024;80:e16-e18.
    >> Share

    December 2023
  151. CSERNALABICS B, Marinescu MS, Maurer L, Kelsch L, et al
    Efficient formation and maintenance of humoral and CD4 T cell immunity targeting the viral capsid in acute-resolving hepatitis E infection.
    J Hepatol. 2023 Dec 26:S0168-8278(23)05370-9. doi: 10.1016/j.jhep.2023.
    >> Share

  152. VAN BOMMEL F, Berg T
    Response to: A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.".
    J Hepatol. 2023 Dec 16:S0168-8278(23)05356-4. doi: 10.1016/j.jhep.2023.
    >> Share

  153. CHE-TO LAI J, Lai-Hung Wong G, Wai-Sun Wong V, Cheuk-Fung Yip T, et al
    Unmet need in screening for hepatitis D virus: time to take action.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05360-6. doi: 10.1016/j.jhep.2023.
    >> Share

  154. SNIJDERS RJ, Stoelinga AE, Gevers TJ, Pape S, et al
    An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
    J Hepatol. 2023 Dec 13:S0168-8278(23)05309-6. doi: 10.1016/j.jhep.2023.
    >> Share

  155. CHEUK-FUNG YIP T, Che-To Lai J, Yam TF, Tse YK, et al
    Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.
    J Hepatol. 2023 Dec 13:S0168-8278(23)05354-0. doi: 10.1016/j.jhep.2023.
    >> Share

    November 2023
  156. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    >> Share


  157. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories.
    J Hepatol. 2023 Nov 27:S0168-8278(23)05285-6. doi: 10.1016/j.jhep.2023.
    >> Share

  158. BALAGOPAL A, Thomas DL
    Genomics on the road to functional cure of hepatitis B.
    J Hepatol. 2023 Nov 18:S0168-8278(23)05276-5. doi: 10.1016/j.jhep.2023.
    >> Share

  159. HUPPE D, Wedemeyer H, Cornberg M
    Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
    J Hepatol. 2023 Nov 3:S0168-8278(23)05234-0. doi: 10.1016/j.jhep.2023.
    >> Share

    October 2023
  160. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
    Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
    J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
    >> Share

  161. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    >> Share

  162. GUAN G, Zhang T, Ning J, Tao C, et al
    Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-alpha-treated patients with chronic hepatitis B.
    J Hepatol. 2023 Oct 17:S0168-8278(23)05175-9. doi: 10.1016/j.jhep.2023.
    >> Share

  163. PANDURANGI S, Malik A, Owens J, Valencia CA, et al
    Deleterious variants in TNFAIP3 are associated with type II and seronegative Pediatric autoimmune hepatitis.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05156-5. doi: 10.1016/j.jhep.2023.
    >> Share

  164. GRONBAEK L, Gronbaek H
    Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
    >> Share

  165. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    >> Share

  166. LU W
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
    >> Share

    September 2023
  167. CHUN HS, Papatheodoridis GV, Lee M, Lee HA, et al
    PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
    J Hepatol. 2023 Sep 19:S0168-8278(23)05096-1. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  168. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    >> Share

  169. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  170. GANE EJ, Dunbar PR, Brooks AE, Zhang F, et al
    Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
    J Hepatol. 2023;78:513-523.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016